Grand Pharmaceutical Group licenses HeartLight X3 laser ablation platform from CardioFocus

Grand Pharmaceutical Group (远大医药) entered into an exclusive licensing agreement with CardioFocus to commercialize the HeartLight X3 laser ablation platform for atrial fibrillation in Greater China, with milestone payments up to $20 million.

“远大医药将以不超过2000万美元的里程碑付款及一定比例的销售提成，引进CardioFocus治疗房颤创新医疗器械HeartLight X3激光消融平台产品在中国大陆、中国香港地区、中国澳门地区的独家商业化权利”beta.zhitongcaijing.com

• 1 source
• beta.zhitongcaijing.com远大医药(00512)独家引进CardioFocus治疗房颤全球创新医疗器械HeartLight X3May 30, 2021

Summarized from public sources; check the original articles before acting on it.